The short answer
Avoid self-starting ephedrine-containing Ephedra while using levalbuterol. Its stimulant effects are a concern even though this exact botanical combination has not been tested.
What this answer covers
Ephedra sinica; ephedrine alkaloid content must be verified, and alkaloid-free products are not equivalent.
- Supplement or preparation
- Ephedra sinica
- Medication ingredient
- levalbuterol
Why this is a meaningful precaution
Levalbuterol labeling cautions about additional adrenergic drugs because harmful cardiovascular effects can occur. Ephedrine alkaloids in Ephedra provide a reason for a pharmacist to review or avoid the supplement.
What the reports can tell us
Ephedra products have been linked to serious cardiovascular and nervous system events. Those reports do not prove a specific interaction rate with levalbuterol or make all botanical preparations identical.
Do not rely on separation
A few hours between products has not been shown to prevent overlapping effects. Do not add Ephedra to treat breathlessness or compensate for worsening asthma.
Keep the inhaled medicine plan
These findings apply to levalbuterol inhalation products. The nebulizer solution and HFA inhaler have their own instructions. Levalbuterol is the R-enantiomer of albuterol; studies of racemic albuterol cannot automatically supply a dose or risk estimate for this product.
Watch symptoms and asthma control
Report new troublesome tremor, racing heartbeat or dizziness after a supplement change. Fainting, chest pain or severe breathing difficulty needs urgent care. Needing levalbuterol more often than usual is a reason to contact the asthma clinician, not to add more stimulants.
Evidence and practical considerations
Side effects & toxicity
The exact label cautions about additional adrenergic drugs; ephedrine-containing Ephedra gives a justified constituent bridge for avoidance review. No exact botanical risk magnitude or protective clock interval is established.
- Exact scope
- Ephedra sinica; ephedrine alkaloid content must be verified, and alkaloid-free products are not equivalent. with Exact levalbuterol hydrochloride nebulized inhalation solution and tartrate HFA inhalation aerosol. Exact RxNorm IN237159, R-enantiomer of albuterol. Hydrochloride nebulizer and tartrate HFA labels are distinct; racemic albuterol is a comparator, not an interchangeable exact drug.
- Medication form and route
- inhalation
- Timing or duration
- Source-specific single-dose, repeated-dose and observational exposures distinguished.
What remains uncertain
- Pharmacovigilance reports are supplement-only, selected and often confounded; not an incidence estimate with levalbuterol.
Factors that may matter: preparation and plant part; clinical indication; dose; other medicines; baseline alertness.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed levalbuterol.
Exact product cardiovascular effects, possible ECG changes, tremor, transient hypokalemia and cautions with additional adrenergic drugs.
How this applies: Exact RxNorm IN237159, R-enantiomer of albuterol. Hydrochloride nebulizer and tartrate HFA labels are distinct; racemic albuterol is a comparator, not an interchangeable exact drug.
No universal supplement dose, interval, event rate or untested formulation equivalence.
Source 2: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed levalbuterol.
Exact product cardiovascular effects, possible ECG changes, tremor, transient hypokalemia and cautions with additional adrenergic drugs.
How this applies: Exact RxNorm IN237159, R-enantiomer of albuterol. Hydrochloride nebulizer and tartrate HFA labels are distinct; racemic albuterol is a comparator, not an interchangeable exact drug.
No universal supplement dose, interval, event rate or untested formulation equivalence.
Source 3: official botanical guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: People considering Ephedra sinica products.
Serious cardiovascular and psychiatric adverse effects reported, including with low-dose or short-term exposure; US ephedrine-alkaloid dietary supplements banned.
How this applies: Only the studied preparation, route and measured endpoints apply; no untested respiratory medication transfer.
Not an levalbuterol co-use study or a population-specific incidence estimate.
Source 4: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 140 adverse-event reports submitted to FDA.
Reports judged related or possibly related included cardiovascular and CNS events, some fatal or disabling.
How this applies: Only the studied preparation, route and measured endpoints apply; no untested respiratory medication transfer.
Selected reports without an exposed-user denominator cannot establish frequency; no levalbuterol coexposure.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Research summary published | |
| Article prepared | |
| Current exact available claims adjudicated using original captures and explicit identity and comparator limits. |
Article revision: 102cd5330222cd70
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.